Ten years of experience of biologics in juvenile idiopathic arthritis: focus for the reasons of withdrawals

Documenti analoghi

• PReS-FINAL-2061: Abatacept in therapy of juvenile idiopathic arthritis in real clinical practice
  di: Arsenyeva, SV, et al.
  Pubblicazione: (2013)
• INFLIXIMAB IN TREATMENT OF REFRACTORY JUVENILE ARTHRITIS
  di: I.P. Nikishina, et al.
  Pubblicazione: (2010-01-01)
• PReS-FINAL-2076: Single centre experience of biologics in clinical practice of systemic juvenile idiopatic arthritis
  di: Kaleda, MI, et al.
  Pubblicazione: (2013)
• Tocilizumab therapy in systemic juvenile idiopathic arthritis – lessons of real clinical practice
  di: Kaleda, Maria I, et al.
  Pubblicazione: (2014)
• An experience of sequental use of three biologics and recombinant growth hormone in a patient with juvenile idiopathic arthritis associated with unsuccessful outcome of hip damage
  di: Nikishina, IP, et al.
  Pubblicazione: (2011)